Hostname: page-component-745bb68f8f-l4dxg Total loading time: 0 Render date: 2025-01-10T13:01:14.393Z Has data issue: false hasContentIssue false
  • English
  • Français

The Efficacy of Asenapine in the Treatment of Bipolar Disorder: a Naturalistic Longitudinal Study Indicating a Favourable Response in Patients with Substance Abuse Comorbidity

Published online by Cambridge University Press:  15 April 2020

I. Cuomo ,
P. Motta ,
C. Fini ,
G.D. Kotzalidis  and
S. De Filippis
I. Cuomo
Affiliation:
NESMOS Department (Neurosciences Mental Health and Sensory Functions), School of Medicine and Psychology Sapienza University Sant'Andrea Hospital, Roma, Italy
P. Motta
Affiliation:
Psychiatry, Villa Von Siebenthal, Genzano di Roma, Italy
C. Fini
Affiliation:
Psychiatry, Villa Von Siebenthal, Genzano di Roma, Italy
G.D. Kotzalidis
Affiliation:
NESMOS Department (Neurosciences Mental Health and Sensory Functions), School of Medicine and Psychology Sapienza University Sant'Andrea Hospital, Roma, Italy
S. De Filippis
Affiliation:
Psychiatry, Villa Von Siebenthal, Genzano di Roma, Italy

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Asenapine is a second-generation antipsychotic approved in Europe for the treatment of moderate to severe manic episodes in adults affected by Bipolar Disorder I (BD I).

Aims

We aimed to assess the efficacy of asenapine in controlling manic, mixed and/or depressive symptoms in an inpatient psychiatric population.

Methods

A total of 119 voluntarily hospitalised patients with DSM-IV-TR BD I diagnosis received flexible asenapine doses ranging 5 to 20 mg/day. Patients were assessed with clinician-rated questionnaires, i.e., Brief Psychiatric Rating Scale (BPRS), Young Mania Rating Scale (YMRS), Hamilton Depression Rating Scale (HAM-D), Hamilton Anxiety Rating Scale (HAM-A), and Global Assessment of Functioning (GAF). Assessment was carried-out at baseline (T0, prior to treatment), and three (T1), seven (T2), 15 (T3), and 30 days (T4) after starting treatment for all clinical scales and at T0 and T4 for the GAF.

Results

Patients improved on all scales (p<.001) across time-points, as shown both by paired-sample comparisons and by applying a repeated-measures, generalized linear model (GLM). Substance abuse was associated with greater reductions in anxious-depressive scores. Side effects were few and not severe.

Conclusion

Asenapine showed effectiveness and safety in a hospitalised bipolar I population. Its effect was greater in the presence of substance abuse.

Type
Article: 1152
Information
European Psychiatry , Volume 30 , Issue S1: Abstracts of the 23rd European Congress of Psychiatry , March 2015 , pp. 1
Copyright
Copyright © European Psychiatric Association 2015
Submit a response

Comments

No Comments have been published for this article.